A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Advanced or Metastatic Squamous Non-Small Cell Lung Cancer · Advanced Head and Neck Squamous Cell Carcinoma · Advanced Esophageal Squamous Cell Carcinoma · Cervical Squamous Cell Carcinoma · Advanced Cutaneous Squamous Cell Carcinoma · Nasopharyngeal Cancinoma (NPC) · Squamous Cell Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • GenesisCare North Shore, Sydney, New South Wales, Australia

  • Westmead Hospital, Westmead, New South Wales, Australia

    Contact: Study coordinator (Pei Ding)
    Contact: Principal Investigator (Pei Dr Ding)
  • ICON Cancer Centre South Brisbane, Brisbane, Queensland, Australia

  • Greenslopes Private Hospital, Greenslopes, Queensland, Australia

    Contact: Study coordinator (Rahul Ladwa)
    Contact: Principal Investigator (Rahul Ladwa)
  • Southern Oncology Clinical Research Unit, Adelaide, South Australia, Australia

    Contact: Study coordinator (Ganessan Kichenadasse)
    Contact: Principal Investigator (Ganessan Kichenadasse)
  • Peninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia

    Contact: Study coordinator (Vinod Ganju)
    Contact: Principal Investigator (Vinod Prof Ganju)
  • Cabrini Health, Malvern, Victoria, Australia

  • Linear Clinical Research, Perth, Western Australia, Australia

    Contact: Study coordinator (Samantha Bowyer)
    Contact: Principal Investigator (Samantha Bowyer)
  • The Institute of Oncology, ARENSIA Exploratory Medicine Phase I Unit, Chisinau, Moldova

    Contact: Study coordinator (Iurie Bulat)
    Contact: Principal Investigator (Iurie Bulat)
  • National Cancer Centre Singapore, Singapore, Singapore

    Contact: Study coordinator (Aaron Tan)
    Contact: Principal Investigator (Aaron Tan)
  • Tan Tock Seng Hospital, Singapore, Singapore

    Contact: Study coordinator (Jens Samol)
    Contact: Principal Investigator (Jens Samol)
  • Chungbuk National University Hospital, Cheongju-si, South Korea

    Contact: Study coordinator (Ki Hyeong Lee)
    Contact: Principal Investigator (Ki Hyeong Lee)
  • CHA Bundang Medical Center, CHA University, Seongnam-si, South Korea

    Contact: Study coordinator (Joo-Hang Kim)
    Contact: Principal Investigator (Joo-Hang Kim)
  • Korea University Anam Hospital, Seoul, South Korea

    Contact: Study coordinator (Yoon Ji Choi)
    Contact: Principal Investigator (Yoon Ji Choi)
  • Severance Hospital, Seoul, South Korea

    Contact: Study coordinator (Hye Ryun Kim)
    Contact: Principal Investigator (Hye Ryun Kim)
  • The Catholic University of Korea St. Vincent's Hospital, Suwon, South Korea

    Contact: Study coordinator (Byoung Yong Shim)
    Contact: Principal Investigator (Byoung Yong Shim)
  • Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan

    Contact: Study coordinator (Jen-Yu Hung)
    Contact: Principal Investigator (Jen-Yu Hung)
  • National Cheng Kung University Hospital, Tainan, Taiwan

    Contact: Study coordinator (Chun-Hui Lee)
    Contact: Principal Investigator (Chun-Hui Lee)
  • Taipei Medical University - Shuang Ho Hospital, Taipei, Taiwan

    Contact: Study coordinator (Wei-Hong Cheng)
    Contact: Principal Investigator (Wei-Hong Cheng)
  • Taipei Veterans General Hospital, Taipei, Taiwan

    Contact: Study coordinator (Yuh-Min Chen)
    Contact: Principal Investigator (Yuh-Min Chen)